| Literature DB >> 30424749 |
Ze-Yu Zhang1, Zhe Liu2, Hui-Hui Deng1, Qin Chen3.
Abstract
BACKGROUND: Vascular dementia is the second most common type of dementia that causes cognitive dysfunction. Acupuncture, an ancient therapy, has been mentioned for the treatment of vascular dementia in previous studies. This study aimed to evaluate the effects of acupuncture in animal models of vascular dementia.Entities:
Keywords: Acupuncture; Meta-analysis; Systematic review; Vascular dementia
Mesh:
Year: 2018 PMID: 30424749 PMCID: PMC6234685 DOI: 10.1186/s12906-018-2345-z
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1Flow diagram of the study selection process. MWM:Morris water maze
Data of 16 included studies
| Trial | Species(Na/Nc) | Age(month) | Weigh(g) | Model | Acupuncture(acupoints) | Control intervention | Outcome assessment | Result |
|---|---|---|---|---|---|---|---|---|
| Wang 2004 [ | SD rats (14/13) | 2~ 3 | 200–250 | 4-VO | EA,20 min/d for 15d, 150HZ, 2 mA, continuous | No treatment | Escape latency | |
| Yu 2005 [ | Wistar rats | NR | 340 ± 40 | EO | manual acupuncture, | Placebo-acupuncture | Escape latency | |
| Shao 2008 [ | SD rats (9/8) | NR | 180–220 | 4-VO | EA,20 min/d for 15 d, 150 HZ, 1–2 mA, Continuous | No treatment | Escape latency | |
| Wang 2009 [ | Wistar rats(11/11) | 10 | 300 ± 40 | EO | manual acupuncture, 30 s/d for 21 d (CV6, CV12, CV17, SP10, ST36) | Placebo-acupuncture | Escape latency | |
| Wei 2011 [ | SD rats(10/10) | NR | 200–250 | 2-VO | EA, 20 min/d for 10 d, 50 HZ,1.0 mA, continuous Waveform (GV14, GV20) | No treatment | Escape latency | |
| Zhao 2011 [ | Wistar rats(10/10) | 4 | 240 ± 20 | EO | manual acupuncture, 30 s/d for 21 d(CV6, CV12, CV17, SP10, ST36) | Placebo-acupuncture | Escape latency | |
| Zhu 2011 [ | SD rats(11/12) | 9 | 460 ± 30 | 2-VO | EA, 20 min/d for 30 d,4HZ, 2.0 mA, continuous waveform (BL23, GV14, GV20) | No treatment | Escape latency | |
| Zhu 2012 [ | SD rats(12/10) | 12 | 400 ± 30 | 2-VO | EA, 20 min/d for 30 d,4 HZ, 2.0 mA, continuous waveform (BL23, GV14, GV20) | No treatment | Escape latency | |
| Zhu 2013 [ | SD rats(6/6) | NR | 432 ± 30 | 2-VO | EA, 20 min/d for 30 d, 4HZ, continuous waveform (BL23, GV14, GV20) | No treatment | Escape latency | |
| Yang 2014 CG [ | Wistar rats (12/12) | NR | 200–250 | 2-VO | manual acupuncture, 360 min/d for 21 d (Frontal region, frontoparietal region and parietal region) | No treatment | Escape latency | |
| Yang 2014 CG [ | Wistar rats (12/12) | NR | 200–250 | 2-VO | manual acupuncture, 360 min/d for 21 d (Frontal region, frontoparietal region and parietal region) | No treatment | Escape latency | |
| Zhang 2014 [ | Wistar rats (10/10) | NR | 300–320 | EO | manual acupuncture, 30 s/d for 21 d (CV6, CV12, CV17, SP10, ST36) | Placebo-acupuncture | Escape latency | |
| Li 2015 [ | Wistar rats (11/11) | NR | 320–360 | EO | manual acupuncture,30 s/d for 14 d (ST36) | Placebo-acupuncture | Escape latency | |
| Li 2015 [ | Wistar rats (10/10) | 2 | 300–320 | EO | manual acupuncture, 30 s/d for 14 d (ST36 | Placebo-acupuncture | Escape latency | |
| Wang 2015 [ | Wister rats(10/10) | NR | 200–220 | 2-VO | manual acupuncture, 30 s/d for 21 d (CV6, CV12, CV17, SP10, ST36) | Placebo-acupuncture | Escape latency | |
| Fang 2016 [ | SD rats(18/18) | 9 | 300–450 | MCAO | EA, 20 min/d for 30 d, 30HZ, 6-15 V, sparse wave (BL23, GV14, GV20) | No treatment | Escape latency | |
| Li 2016 [ | Wister rats (14/14) | NR | 270–320 | 2-VO | manual acupuncture, 30 s/d for 14 d (ST36) | Placebo-acupuncture | Escape latency |
Na number of animals in the acupuncture group, EA electroacupuncture, Nc number of animals in the control group, SD Sprague Dawley, 4-VO 4-vessel occlusion, EO embolic occlusion, 2-VO bilateral common carotid artery occlusion, NR no record, PG positive control group, CG cluster-needling group, MCAO middle cerebral artery occlusion
Methodological quality assessment of the included studies
| Study | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Wang 2004 [ | Y | Y | Y | Y | N | Y | N | N | N | N | 5 |
| Yu 2005 [ | Y | Y | Y | Y | N | Y | N | N | N | N | 5 |
| Shao 2008 [ | Y | Y | Y | N | N | U | N | N | N | Y | 4 |
| Wang 2009 [ | Y | N | Y | Y | N | Y | N | N | Y | N | 5 |
| Wei 2011 [ | Y | Y | Y | Y | N | Y | N | N | Y | N | 6 |
| Zhao 2011 [ | Y | N | Y | Y | N | U | N | N | N | Y | 4 |
| Zhu 2011 [ | Y | N | Y | Y | N | Y | N | N | N | Y | 5 |
| Zhu 2012 [ | Y | Y | Y | N | N | Y | N | N | Y | Y | 6 |
| Zhu 2013 [ | Y | Y | Y | Y | N | Y | N | N | N | N | 6 |
| Yang 2014 [ | Y | Y | Y | Y | N | Y | N | N | Y | Y | 8 |
| Zhang 2014 [ | Y | N | Y | Y | N | U | N | N | Y | N | 4 |
| Li 2015 [ | Y | Y | Y | Y | Y | Y | N | N | N | Y | 7 |
| Li 2015 [ | Y | N | Y | N | Y | Y | N | N | N | N | 4 |
| Wang 2015 [ | Y | Y | Y | Y | N | Y | N | N | Y | N | 6 |
| Fang 2016 [ | Y | Y | Y | Y | N | U | N | N | Y | Y | 6 |
| Li 2016 [ | Y | Y | Y | Y | N | Y | N | N | Y | N | 6 |
(1) Peer-reviewed journal. (2) Temperature control. (3) Animals were randomly allocated. (4) Blind established model. (5) Blinded outcome assessment. (6) Anesthetics used without marked intrinsic neuroprotective properties. (7) Animal model (diabetic, advanced age or hypertensive). (8) Calculation of sample size. (9) Statement of compliance with animal welfare regulations. (10) Possible conflicts of interest
Y, Yes(low risk bias); N, No(high risk bias); U, Unclear
Fig. 2Forest plot showed that escape latency decreases with acupuncture therapies in vascular models. Effect of acupuncture on outcomes of the water maze: effect on (a) escape latency time versus the control group; (b) escape latency time versus nimodipine; (c) duration in original platform; (d) frequency of crossing former platform
Subgroup analysis for the effect of acupuncture on reducing escape latency time
| SMD | LL | HL | Degrees of freedom | Heterogeneity | Effect size | |||
|---|---|---|---|---|---|---|---|---|
| I2 | Z | P | ||||||
| Species | SR | −3.33 | −5.18 | −1.47 | 5 | 92.10% | 3.52 | |
| WR | −2.85 | −3.79 | −1.91 | 5 | 73.50% | 5.93 | ||
| Modeling | 2-VO | −2.97 | −4.21 | − 1.73 | 6 | 85.80% | 4.69 | |
| 4-VO | −3.36 | −8.63 | 1.92 | 1 | 94.30% | 1.25 | ||
| EO | −2.38 | −3.82 | −0.95 | 1 | 65.80% | 3.26 | ||
| MCAO | −5.19 | −6.58 | −3.79 | 0 | – | 7.29 | ||
| Methods | EA | −3.05 | −4.56 | −1.53 | 6 | 90.50% | 3.94 | |
| MA | −3.11 | −4.23 | −2.00 | 4 | 75.90% | 5.47 | ||
| OVERALL | −3.06 | −4.04 | −2.09 | 11 | 87.10% | 6.04 | ||
SR Sprague–Dawley Rats, WR Wister Rats, 2-VO bilateral common carotid artery occlusion, VO 4-vessel occlusion, EO embolic occlusion, MCAO middle cerebral artery occlusion, EA Electroacupuncture, MA Manual acupuncture
Fig. 3Begg’s test for the outcome of escape latency
Proposed mechanisms
| Study | Findings & Proposed mechanisms |
|---|---|
| Wang 2004 [ | • Reduced NO, NOS and MDA |
| Shao 2008 [ | Increased AVP and SS |
| Wang 2009 [ | • Up-regulating the expression of Bcl-2 |
| Wei 2011 [ | Promoting synaptic function and structure |
| Zhao 2011 [ | Enhanced hexokinase, pyruvate kinase and glucose 6 phosphate dehydrogenase activities |
| Zhu 2011 [ | Inhibiting expression of p53 and Noxa |
| Zhu 2012 [ | Increased p70S6K and ribosomal protein S6 |
| Zhu 2013 [ | Increased mTOR and eIF4E |
| Yang 2014 [ | Increased hippocampal ACh, DA, and 5-HT |
| Zhang 2014 [ | Increased CBF |
| Li 2015 [ | Increase pyramidal neuron number in hippocampal CA1 area |
| Li 2015 [ | • Inhibited PDE activity |
| Wang 2015 [ | Enhanced Nrf2 |
| Fang 2016 [ | Decreased TNF-α mRNA, IL-6 mRNA and IL-1β mRNA |
| Li 2016 [ | • Increased complex I, II, IV and cox IV |
NO nitric oxide, NOS nitric oxide synthase, MDA malondialdehyde, GSH-Px glutathione peroxidase, AVP arginine vasopressin, SS somatostatin, Bcl-2 B-cell lymphoma-2, Bax Bcl-2 associated X protein, P53 Tumor protein P53, P70S6K P70 ribosomal protein S6 kinase, mTOR mammalian target of rapamycin, eIF4E eukaryotic translation initiation factor, Ach acetylcholine, DA dopamine, 5-HT 5-hydroxytryptamine, CBF cerebral blood flow, PDE phosphodiesterase, ERK extracellular signal-regulated kinase, cAMP 3′,5′-cyclic AMP/protein kinaseA, PKA protein kinaseA, CREB cAMP/PKA/cAMP response element binding protein, Nrf2 nuclear factor erythroid-related factor 2, TNF tumor necrosis factor, IL interleukin, coxIV cytochrome oxidase IV, ROS reactive oxygen species